“…Two participants discontinued the study; the first participant due to a TEAE of upper respiratory infection, which occurred after receiving moxifloxacin, and the second participant discontinued the study due to a family emergency before they would have received maribavir 1,200 mg. There was a total of 133 TEAEs reported (13,20,29, and 71, among participants receiving placebo, moxifloxacin 400 mg, maribavir 100 mg, and maribavir 1,200 mg, respectively). All TEAEs were mild in intensity.…”